Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen γ′ levels

Blood

Volumn 106, Issue 13, 2005, Pages 4176-4183

  De Willige, Shirley Uitte ^a   De Visser, Marieke C H ^a   Houwing Duistermaat, Jeanine J ^a   Rosendaal, Frits R ^a   Vos, Hans L ^a   Bertina, Rogier M ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN;

ADOLESCENT; AGED; ARTICLE; BINDING SITE; CHROMATIN; CONFIDENCE INTERVAL; CONSENSUS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; FIBRIN FORMATION; FIBRINOGEN BLOOD LEVEL; GENE CLUSTER; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; HAPLOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 28844473918     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-05-2180     Document Type: Article

References (67)

1. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci. 2001;936:11-30.
2. Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci. 2001;936:291-311.
3. Gaffney PJ, Whitaker AN. Fibrin crosslinks and lysis rates. Thromb Res. 1979;14:85-94.
4. Reed GL, Matsueda GR, Haber E. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin. Thromb Haemost. 1992;68:315-320.
5. Siebenlist KR, Mosesson MW. Progressive crosslinking of fibrin gamma chains increases resistance to fibrinolysis. J Biol Chem. 1994;269:28414-28419.
6. Herrick S, Blanc-Brude O, Gray A, Laurent G. Fibrinogen. Int J Biochem Cell Biol. 1999;31:741-746.
7. Kant JA, Fornace AJ Jr, Saxe D, et al. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci U S A. 1985;82:2344-2348.
8. Nickerson D. Seattle SNPs: NHLBI Program for Genomic Applications, UW-FHCRC, Seattle, WA. http://pga.gs.washington.edu. Accessed April 15, 2003.
9. Fu Y, Grieninger G. Fib420: a normal human variant of fibrinogen with two extended alpha chains. Proc Natl Acad Sci U S A. 1994;91:2625-2628.
10. Wolfenstein-Todel C, Mosesson MW. Carboxyterminal amino acid sequence of a human fibrinogen gamma-chain variant (gamma′). Biochemistry. 1981;20:6146-6149.
11. Koster T, Rosendaal FR, Reitsma PH, et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis: a case-control study of plasma levels and DNA polymorphisms - the Leiden Thrombophilia Study (LETS). Thromb Haemost. 1994;71:719-722.
12. van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost. 2003;1:2677-2678.
13. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost. 2003;89:601-609.
14. Mosesson MW. Dysfibrinogenemia and thrombosis. Semin Thromb Hemost. 1999;25:311-319.
15. Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci. 2001;936:89-90.
16. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia: report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost. 1995;73:151-161.
17. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503-1506.
18. van der Meer FJ, Koster T, Vandenbroucke JP, Briët E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost. 1997;78:631-635.
19. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978-989.
20. Crawford DC, Carlson CS, Rieder MJ, et al. Haplotype diversity across 100 candidate genes for inflammation, lipid metabolism, and blood pressure regulation in two populations. Am J Hum Genet. 2004;74:610-622.
21. Chung DW, Davie EW. Gamma and gamma′ chains of human fibrinogen are produced by alternative mRNA processing. Biochemistry. 1984;23:4232-4236.
22. Fornace AJ Jr, Cummings DE, Comeau CM, Kant JA, Crabtree GR. Structure of the human gamma-fibrinogen gene: alternate mRNA splicing near the 3′ end of the gene produces gamma A and gamma B forms of gamma-fibrinogen. J Biol Chem. 1984;259:12826-12830.
23. Wolfenstein-Todel C, Mosesson MW. Human plasma fibrinogen heterogeneity: evidence for an extended carboxyl-terminal sequence in a normal gamma chain variant (gamma′). Proc Natl Acad Sci U S A. 1980;77:5069-5073.
24. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal. 1999;14:143-149.
25. Lovely RS, Falls LA, Al Mondhiry HA, et al. Association of γA/gamma′ fibrinogen levels and coronary artery disease. Thromb Haemost. 2002;88:26-31.
26. Meh DA, Siebenlist KR, Brennan SO, Holyst T, Mosesson MW. The amino acid sequence in fibrin responsible for high affinity thrombin binding. Thromb Haemost. 2001;85:470-474.
27. Lovely RS, Moaddel M, Farrell DH. Fibrinogen gamma′ chain binds thrombin exosite II. J Thromb Haemost. 2003;1:124-131.
28. Epstein MP, Satten GA. Inference on haplotype effects in case-control studies using unphased genotype data. Am J Hum Genet. 2003;73:1316-1329.
29. Duncan RD, Epstein MP, Satten GA. Casecontrol haplotype inference. Version 1.0. Atlanta: Emory University School of Medicine; 2004.
30. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19:251-253.
31. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
32. Schneider S, Roessli D, Excoffier L. Arlequin: a software for population genetics data analysis. Geneva, Switzerland: University of Geneva, Genetics and Biometry Laboratory, Department of Anthropology; 2000.
33. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost. 2003;89:493-498.
34. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
35. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deepvein thrombosis. Lancet. 1995;345:152-155.
36. van Hylckama Vlieg A, van der Linden I, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood. 2000;95:3678-3682.
37. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342:696-701.
38. Kamphuisen PW, Eikenboom JC, Vos HL, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost. 1999;81:680-683.
39. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293:2352-2361.
40. Green FR. Fibrinogen polymorphisms and atherothrombotic disease. Ann N Y Acad Sci. 2001;936:549-559.
41. Mannila MN, Eriksson P, Lundman P, et al. Contribution of haplotypes across the fibrinogen gene cluster to variation in risk of myocardial infarction. Thromb Haemost. 2005;93:570-577.
42. Connor JM, Fowkes FG, Wood J, et al. Genetic variation at fibrinogen loci and plasma fibrinogen levels. J Med Genet. 1992;29:480-482.
43. Beyer K, Dandekar T, Keller W. RNA ligands selected by cleavage stimulation factor contain distinct sequence motifs that function as downstream elements in 3′-end processing of premRNA. J Biol Chem. 1997;272:26769-26779.
44. Humphries SE. Genetic regulation of fibrinogen. Eur Heart J. 1995;16(suppl A):16-19.
45. de Lange M, Snieder H, Ariens RA, Spector TD, Grant PJ. The genetics of haemostasis: a twin study. Lancet. 2001;357:101-105.
46. Dunn EJ, Ariens RA, de Lange M, et al. Genetics of fibrin clot structure: a twin study. Blood. 2004;103:1735-1740.
47. Souto JC, Almasy L, Borrell M, et al. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation. 2000;101:1546-1551.
48. Yang Q, Tofler GH, Cupples LA, et al. A genome-wide search for genes affecting circulating fibrinogen levels in the Framingham Heart Study. Thromb Res. 2003;110:57-64.
49. Soria JM, Almasy L, Souto JC, et al. A genome search for genetic determinants that influence plasma fibrinogen levels. Arterioscler Thromb Vasc Biol. 2005;25:1287-1292.
50. Cooper AV, Standeven KF, Ariëns RA. Fibrinogen gamma-chain splice variant γ′ alters fibrin formation and structure. Blood. 2003;102:535-540.
51. Moaddel M, Farrell DH, Daugherty MA, Fried MG. Interactions of human fibrinogens with factor XIII: roles of calcium and the gamma′ peptide. Biochemistry. 2000;39:6698-6705.
52. Falls LA, Farrell DH. Resistance of γA/γ′ fibrin clots to fibrinolysis. J Biol Chem. 1997;272:14251-14256.
53. Mosesson MW, Siebenlist KR, Hainfeld JF, Wall JS. The covalent structure of factor XIIIa crosslinked fibrinogen fibrils. J Struct Biol. 1995;115:88-101.
54. Mosesson MW. Fibrinogen gamma chain functions. J Thromb Haemost. 2003;1:231-238.
55. Liu CY, Nossel HL, Kaplan KL. The binding of thrombin by fibrin. J Biol Chem. 1979;254:10421-10425.
56. Mosesson MW. Antithrombin I: inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost. 2003;89:9-12.
57. Meh DA, Siebenlist KR, Mosesson MW. Identification and characterization of the thrombin binding sites on fibrin. J Biol Chem. 1996;271:23121-23125.
58. Seegers WH, Nieft M, Loomis EC. Note on the adsorption of thrombin on fibrin. Science. 1945;101:520-521.
59. Klein PD, Seegers WH. The nature of plasma antithrombin activity. Blood. 1950;5:742-752.
60. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
61. Siebenlist KR, Mosesson MW, Hernandez I, et al. Studies on the basis for the properties of fibrin produced from fibrinogen-containing γ′ chains. Blood. 2005;106:2730-2736.
62. de Bosch NB, Mosesson MW, Ruiz-Saez A, Echenagucia M, Rodriguez-Lemoin A. Inhibition of thrombin generation in plasma by fibrin formation (antithrombin I). Thromb Haemost. 2002;88:253-258.
63. Drouet L, Paolucci F, Pasqualini N, et al. Plasma gamma′/gamma fibrinogen ratio, a marker of arterial thrombotic activity: a new potential cardiovascular risk factor? Blood Coagul Fibrinolysis. 1999;(suppl 1):S35-S39.
64. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation. 2003;107:1117-1122.
65. Baumann RE, Henschen AH. Human fibrinogen polymorphic site analysis by restriction endonuclease digestion and allele-specific polymerase chain reaction amplification: identification of polymorphisms at positions A alpha 312 and B beta 448. Blood. 1993;82:2117-2124.
66. Standeven KF, Grant PJ, Carter AM, et al. Functional analysis of the fibrinogen Aα Thr312Ala polymorphism: effects on fibrin structure and function. Circulation. 2003;107:2326-2330.
67. Carter AM, Catto AJ, Kohler HP, et al. α-Fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood. 2000;96:1177-1179.